[1] LIBBY P. The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease. Nat Rev Cardiol. 2021;18(10):683-684.
[2] DROSOS I, PAVLAKI M, ORTEGA CARRILLO MDP, et al. Increased Lymphangiogenesis and Lymphangiogenic Growth Factor Expression in Perivascular Adipose Tissue of Patients with Coronary Artery Disease. J Clin Med. 2019;8(7):1000.
[3] MIYAZAKI T, MIYAZAKI A. Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg? Front Cardiovasc Med. 2021;8:701229.
[4] D’AMORE PA, ALCAIDE P. Macrophage efferocytosis with VEGFC and lymphangiogenesis: rescuing the broken heart. J Clin Invest. 2022; 132(9):e158703.
[5] BOZOGLU T, LEE S, ZIEGLER T, et al. Endothelial Retargeting of AAV9 In Vivo. Adv Sci (Weinh). 2022;9(7):e2103867.
[6] 谢佳,杨毅宁,马依彤,等.重组9型腺相关病毒载体转染动脉粥样硬化模型小鼠主动脉:最佳在体表达时间点的确定[J].中国组织工程研究,2015,19(5):733-738.
[7] KANG WS, KWON JS, KIM HB, et al. A macrophage-specific synthetic promoter for therapeutic application of adiponectin. Gene Ther. 2014; 21(4):353-362.
[8] ENGELEN SE, ROBINSON AJB, ZURKE YX, et al. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. 2022;19(8):522-542.
[9] HONG CG, FLORIDA E, LI H, et al. Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis. Front Cardiovasc Med. 2023;9:1023651.
[10] TANG C, DENG L, LUO Q, et al. Identification of oxidative stress-related genes and potential mechanisms in atherosclerosis. Front Genet. 2023;13:998954.
[11] LIBBY P. The changing landscape of atherosclerosis. Nature. 2021; 592(7855):524-533.
[12] RAN S, MONTGOMERY KE. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel). 2012;4(3):618-657.
[13] MIYAZAKI T, TAKETOMI Y, HIGASHI T, et al. Hypercholesterolemic Dysregulation of Calpain in Lymphatic Endothelial Cells Interferes With Regulatory T-Cell Stability and Trafficking. Arterioscler Thromb Vasc Biol. 2023;43(2):e66-e82.
[14] MORONI F, AMMIRATI E, NORATA GD, et al. The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. Mediators Inflamm. 2019;2019:7434376.
[15] ORECCHIONI M, KOBIYAMA K, WINKELS H, et al. Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production. Science. 2022;375(6577):214-221.
[16] FENG X, DU M, LI S, et al. Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in macrophages to reduce atherosclerosis in ApoE-/- mice. Phytomedicine. 2023;112:154684.
[17] HATADA I, MORITA S, HORII T. CRISPR/Cas9. Methods Mol Biol. 2023; 2637:41-47.
[18] EL MARJOU F, JOUHANNEAU C, KRNDIJA D. Targeted Transgenic Mice Using CRISPR /Cas9 Technology. Methods Mol Biol. 2021;2214:125-141.
[19] LIU B, JING Z, ZHANG X, et al. Large-scale multiplexed mosaic CRISPR perturbation in the whole organism. Cell. 2022;185(16):3008-3024.
[20] WEN JH, LI DY, LIANG S, et al. Is LysM-Cre a good candidate Cre for knocking out Atg5 gene in mice? Front Immunol. 2022;13:964496.
[21] KARKKAINEN MJ, HAIKO P, SAINIO K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5(1):74-80.
[22] JÄSCHKE N, BÜNING H. Adeno-Associated Virus Vector Design-Moving the Adeno-Associated Virus to a Bioengineered Therapeutic Nanoparticle. Hematol Oncol Clin North Am. 2022;36(4):667-685.
[23] CHEN X, HE Y, TIAN Y, et al. Different Serotypes of Adeno-Associated Virus Vector- and Lentivirus-Mediated Tropism in Choroid Plexus by Intracerebroventricular Delivery. Hum Gene Ther. 2020;31(7-8):440-447.
[24] ZHANG H, LI T, SUN Y, et al. Perfecting Targeting in CRISPR. Annu Rev Genet. 2021;55:453-477.
[25] IQBAL AJ, MCNEILL E, KAPELLOS TS, et al. Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo. Blood. 2014;124(15):e33-44.
[26] LI AC, GUIDEZ FR, COLLIER JG, et al. The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun. J Biol Chem. 1998; 273(9):5389-5399.
[27] HORVAI A, PALINSKI W, WU H, et al. Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci U S A. 1995; 92(12):5391-5395.
[28] HE W, QIANG M, MA W, et al. Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther. 2006;17(9):949-959.
[29] LEVIN MC, LIDBERG U, JIRHOLT P, et al. Evaluation of macrophage-specific promoters using lentiviral delivery in mice. Gene Ther. 2012; 19(11):1041-1047.
[30] PETROVA TV, KOH GY. Biological functions of lymphatic vessels. Science. 2020;369(6500):eaax4063.
[31] KAIPAINEN A, KORHONEN J, MUSTONEN T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92(8): 3566-3570.
[32] LAWRANCE W, BANERJI S, DAY AJ, et al. Binding of Hyaluronan to the Native Lymphatic Vessel Endothelial Receptor LYVE-1 Is Critically Dependent on Receptor Clustering and Hyaluronan Organization. J Biol Chem. 2016;291(15):8014-8030.
[33] MARUYAMA Y, MARUYAMA K, KATO Y, et al. The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions. Invest Ophthalmol Vis Sci. 2014;55(8):4813-4822.
[34] MAN JJ, BECKMAN JA, JAFFE IZ. Sex as a Biological Variable in Atherosclerosis. Circ Res. 2020;126(9):1297-1319.
|